RenovoRx (RNXT) Q1 2026 Earnings Transcript

RenovoRx reported record Q1 2026 revenue of $563 thousand, up 136% sequentially, with gross margin of 85.1% and 16 active commercial cancer centers versus 8 at year-end 2025. Management reiterated full-year 2026 revenue guidance of $3 million to $4 million and expects Q2 revenue to exceed Q1 as more sites convert from clinical to commercial use. The company also said TIGER-PACT enrollment is 93% complete, with final trial data still expected in mid-to-late 2027 and cash of $12.4 million supporting runway into 2027.

Analysis

This print is less about a one-quarter revenue beat and more about evidence that the company has crossed the “clinical curiosity” threshold into a repeatable procurement cycle. The important second-order signal is the doubling of active centers alongside repeat orders: that combination usually matters more than headline revenue because it suggests the bottleneck is no longer physician enthusiasm, but institutional workflow and conversion cadence. If that cadence holds, revenue should start to scale nonlinearly over the next 2-3 quarters as each new center compounds procedure volume rather than contributing a one-time activation bump.

The real hidden catalyst is the trial-site-to-commercial conversion pathway. Those sites already have internal familiarity with the device, trained operators, and prior institutional evidence, so their go-live friction should be meaningfully lower than first-time centers. That creates a better-than-standard medtech rollout dynamic: lower customer acquisition cost, faster time-to-first-order, and a stronger probability of repeat usage, which is why gross margin can stay high even if top-line growth remains lumpy quarter to quarter.

The main risk is not clinical failure in the near term; it is conversion slippage and institutional procurement timing. A handful of delayed VAC approvals or slower-than-expected commercial ordering could create a misleadingly weak quarter even if the underlying demand story remains intact. Also, because the stock is now trading on execution credibility, any variance in SG&A or a perception that expenses are not as fixed as management suggests could compress the multiple quickly despite improving fundamentals.

Consensus may be underestimating how much of the value is already being de-risked before the Phase III readout. If the market is still treating this as a binary clinical story, that is a mistake; the better framework is a commercial rollout with an embedded option on eventual label/reimbursement expansion. The upside case is not merely success in TIGER-PACT, but a much larger installed base by the time readout arrives, which would force a re-rate from story stock to emerging commercial platform.

Key Decisions for Investors

• Long RNXT into the next 1-2 quarters if liquidity allows; the setup is a commercial acceleration trade, not a binary readout trade. Risk/reward is attractive if active centers keep compounding toward 36 by year-end, but trim if center adds or repeat orders stall for a full quarter.
• Prefer call spreads over outright stock in RNXT for the next 3-6 months; upside is tied to a re-rating on execution while downside is sensitive to any conversion delay. A defined-risk structure captures the asymmetry without overexposing to trial-timing noise.
• If already long, add on pullbacks only after confirming center growth and Q2 above Q1; the best entry is a post-print or post-approval dip, not momentum chasing. The trade works only if the market continues to see the commercial funnel widening faster than opex.
• Avoid shorting RNXT on valuation alone; the second-order squeeze risk is high because the catalyst path includes repeat orders plus trial-site conversions, both of which can advance before the readout. A short only makes sense on evidence of center attrition or a material slowdown in order frequency.